Development of lentiviral vectors for gene therapy for human diseases

Blood

Volumn 95, Issue 8, 2000, Pages 2499-2504

  Buchschacher Jr , Gary L ^a   Wong Staal, Flossie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIS ACTING ELEMENT; VIRUS VECTOR;

EXPRESSION VECTOR; GENE THERAPY; GENE TRANSFER; LENTIVIRINAE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIROLOGY; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0343851161     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.8.2499     Document Type: Review

References (53)

1. Miller AD. Human gene therapy comes of age. Nature. 1992;357:455-460.
2. Culver KW, Blaese RM. Gene therapy and cancer. Trends Genet. 1994;10:174-178.
3. Crystal RG. Transfer of genes to human: early lessons and obstacles to success. Science. 1995; 270:404-410.
4. Coffin JM. Retroviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, et al, eds. Fundamental Virology. 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1996:763-843.
5. Panganiban AT. Retroviral reverse transcription and DNA integration. Semin Virol. 1990;1:187-194.
6. Miller AD. Retrovirus packaging cells. Hum Gene Ther. 1990;1:5-14.
7. Luciw PA. Human immunodeficiency viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fundamental Virology. 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1996:845-916.
8. Sodroski J, Rosen C, Wong-Staal F, et al. Transacting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science. 1985;227:171-173.
9. Emerman M, Vazeux R, Peden K. The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization. Cell. 1989;57:1155-1165.
10. Cochrane AW, Chen C, Rosen CA. Specific interaction of the human immunodeficiency virus Rev protein with a structured region in the env mRNA. Proc Natl Acad Sci U S A. 1990;87:1198-1202.
11. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol. 1994;68: 510-516.
12. Gallay P, Swingler S, Song J, Bushman F, Trono D. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell. 1995;83:569-576.
13. Bukrinsky MI, Haggerty S, Dempsey MP, at al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature. 1993;365:666-669.
14. Heinzinger NK, Bukrinsky MI, Haggerty SA, et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A. 1994;91:7311-7315.
15. Kondo E, Mammano F, Cohen EA, Gottlinger HG. The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous particles. J Virol. 1995;69: 2759-2764.
16. Vodicka MA, Koepp DM, Silver PA, Emerman M. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev. 1998;12:175-185.
17. 1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol. 1998;72:3161-3168.
18. Helseth E, Kowalski M, Gabuzda D, Olshevsky U, Haseltine W, Sodroski J. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol. 1990;64:2416-2420.
19. Page KA, Landau NR, Littman DR. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol. 1990;64: 5270-5276.
20. Freed EO, Delwart EL, Buchschacher GL Jr, Panganiban AT. A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein 41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci U S A. 1992;89:70-74.
21. Yee J, Miyanohara A, LaPorte P, Bouic K, Burns JC, Friedman T. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci U S A. 1994;91:9564-9568.
22. Buchschacher GL Jr, Panganiban AT. Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol. 1992;66:2731-2739.
23. Pozansky M, Lever A, Bergeron L, Haseltine W, Sodroski J. Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector. J Virol. 1991;65:532-536.
24. Parolin C, Dorfman T, Palu G, Gottlinger H, Sodroski J. Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J Virol. 1994;68:3888-3895.
25. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272: 263-267.
26. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A. 1996;93:11,382-11,388.
27. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 1997;71:6641-6649.
28. Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A. 1997;94:10,319-10,323.
29. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet. 1997;17:314-317.
30. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science. 1999;283:682-686.
31. Fahlman C, Woods NB, Mikkola H, et al. Lentiviral gene transfer into secondary NOD/SCID re-populating cells and lentiviral vector design for expression in CD34+ cells (abstract). Blood. 1999;94:1600a.
32. Mcbride MS, Schwartz MD, Panganiban AT. Efficient encapsidation of human immunodeficiency virus type 1 vectors and further characterization of cis elements required for encapsidation. J Virol. 1997;71:4544-4554.
33. Srinivasakumar N, Chazal N, Helga-Maria C, Prasad S, Hammarskjold M, Rekosh D. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol. 1997;71:5841-5848.
34. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol. 1998;72:811-816.
35. Yu H, Rabson AB, Kaul M, Ron Y, Dougherty JP. Inducible human immunodeficiency virus type 1 packaging cell lines. J Virol. 1996;70:4530-4537.
36. Corbeau P, Kraus G, Wong-Staal F. Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable packaging cell line. Proc Natl Acad Sci U S A. 1996;93: 14,070-14,075.
37. Poeschla E, Gilbert J, Li X, Huang S, Ho A. Wong-Staal F. Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors. J Virol. 1998;72:6527-6536.
38. Rizvi TA, Panganiban AT. Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles. J Virol. 1993;67:2681-2688.
39. Buchschacher GL Jr. Molecular targets of gene transfer therapy for HIV infection. JAMA. 1993; 269:2880-2886.
40. Corbeau P, Kraus G, Wong-Staal F. Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system. Gene Ther. 1998;5:99-104.
41. White SM, Renda M, Nam NY, et al. Lentivirus vectors using human and simian immunodeficiency virus elements. J Virol. 1999;73:2832-2840.
42. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med. 1998;4:354-357.
43. Johnston JC, Gasmi M, Lim LE, et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol. 1999;73:4991-5000.
44. Pederson NC. The feline immunodeficiency virus. In: Levy JA, ed. The Retroviridae. New York: Plenum Press; 1993:181-228.
45. Johnston J, Power C. Productive infection of human peripheral blood mononuclear cells by feline immunodeficiency virus: implications for vector development. J Virol. 1999;73:2491-2498.
46. Olsen JC. Gene transfer vectors derived from equine infectious anemia virus. Gene Ther. 1998; 5:1481-1487.
47. Takahashi M, Miyoshi H, Verma IM, Gage FH. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J Virol. 1999;73: 7812-7816.
48. Yamada K, Olsen JC, Walsh CE. Functional correction of Fanconi anemia group C (FANCC) hematopoietic cells by the use of a novel lentiviral vector (abstract). Blood. 1999;94:765a.
49. Temin HM. Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum Gene Ther. 1990;1:111-123.
50. Venkatesh LK, Arens MQ, Subramanian T, Chinnadurai G. Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector. Proc Natl Acad Sci U S A. 1990; 87:8746-8750.
51. Chong H, Starkey W, Vile RG. A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences. J Virol. 1998;72:2663-2670.
52. Patience C, Takeuchi Y, Cosset F, Weiss RA. Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells. J Virol. 1998;72:2671-2676.
53. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286:2244-2245.